{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:3355"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:3355","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Role of Interleukin 21 in CD4 T cell regulation","abstract":"IL-21 is crucial for anti-viral defense, the germinal center reaction and anti-tumour immunity. Conversely, it has been implicated in various autoimmune conditions, including type-1 diabetes. This study set out to explore how IL-21 influences CD4 T cell immune responses, with particular emphasis on its ability to counteract Treg-mediated suppression. These experiments revealed that IL-21 acted on conventional CD4 T cells to release them from suppression. This was associated with loss of Treg homeostasis, as IL-21 was able to inhibit IL-2 production and could substitute for IL-2 in conventional but not regulatory T cells. Analysis of how CD4 T cell responses are controlled was broadened by investigation of the CTLA-4 pathway, a major regulator of T cell immunity. We showed that CTLA-4 could decrease the level of CD86 expression on APCs by trans-endocytosis in vivo, thereby limiting T cell CD28 signalling. In a further development, we showed that IL-21 could directly upregulate CD86 expression by B cells, illustrating the opposing functions of CTLA-4 and IL-21. Finally, we explored how the nature of T cell activation influences cytokine production and pathogenicity. These experiments revealed that IL-21 production by CD4 T cells was strongly induced during responses driven by DCs, whilst stimulation with B cells promoted IFNγ expression. Moreover, T cells activated in the presence of DCs were profoundly diabetogenic in an adoptive transfer system, unlike those co-stimulated with B cells. These data provide new insight into the regulation of CD4 T cell responses and how levels of IL-21 produced in vivo could modulate the balance between tolerance and immunity.","abstract_html":"IL-21 is crucial for anti-viral defense, the germinal center reaction and anti-tumour immunity. Conversely, it has been implicated in various autoimmune conditions, including type-1 diabetes. This study set out to explore how IL-21 influences CD4 T cell immune responses, with particular emphasis on its ability to counteract Treg-mediated suppression. These experiments revealed that IL-21 acted on conventional CD4 T cells to release them from suppression. This was associated with loss of Treg homeostasis, as IL-21 was able to inhibit IL-2 production and could substitute for IL-2 in conventional but not regulatory T cells. Analysis of how CD4 T cell responses are controlled was broadened by investigation of the CTLA-4 pathway, a major regulator of T cell immunity. We showed that CTLA-4 could decrease the level of CD86 expression on APCs by trans-endocytosis in vivo, thereby limiting T cell CD28 signalling. In a further development, we showed that IL-21 could directly upregulate CD86 expression by B cells, illustrating the opposing functions of CTLA-4 and IL-21. Finally, we explored how the nature of T cell activation influences cytokine production and pathogenicity. These experiments revealed that IL-21 production by CD4 T cells was strongly induced during responses driven by DCs, whilst stimulation with B cells promoted IFNγ expression. Moreover, T cells activated in the presence of DCs were profoundly diabetogenic in an adoptive transfer system, unlike those co-stimulated with B cells. These data provide new insight into the regulation of CD4 T cell responses and how levels of IL-21 produced in vivo could modulate the balance between tolerance and immunity.","abstract_has_math":false,"creators":["Attridge, Kesley Blair"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2012,"date_issued":"2012-07","date_published":"2012-07","updated_at":"2026-11-19T09:27:08Z","subjects":["R Medicine (General)","RC Internal medicine"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/3355/1/Attridge_12_PhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A3355","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["na"]},{"key":"dc:creator","label":"Author","values":["Attridge, Kesley Blair"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2012-07"]},{"key":"dc:date.issued","label":"Date","values":["2012-07"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","School of Immunity and Infection"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/3355/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["R Medicine (General)","RC Internal medicine"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/3355/1/Attridge_12_PhD.pdf","http://etheses.bham.ac.uk//id/eprint/3355/2/Decl_IS_Attridge_12_PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["IL-21 is crucial for anti-viral defense, the germinal center reaction and anti-tumour immunity. Conversely, it has been implicated in various autoimmune conditions, including type-1 diabetes. This study set out to explore how IL-21 influences CD4 T cell immune responses, with particular emphasis on its ability to counteract Treg-mediated suppression. These experiments revealed that IL-21 acted on conventional CD4 T cells to release them from suppression. This was associated with loss of Treg homeostasis, as IL-21 was able to inhibit IL-2 production and could substitute for IL-2 in conventional but not regulatory T cells. Analysis of how CD4 T cell responses are controlled was broadened by investigation of the CTLA-4 pathway, a major regulator of T cell immunity. We showed that CTLA-4 could decrease the level of CD86 expression on APCs by trans-endocytosis in vivo, thereby limiting T cell CD28 signalling. In a further development, we showed that IL-21 could directly upregulate CD86 expression by B cells, illustrating the opposing functions of CTLA-4 and IL-21. Finally, we explored how the nature of T cell activation influences cytokine production and pathogenicity. These experiments revealed that IL-21 production by CD4 T cells was strongly induced during responses driven by DCs, whilst stimulation with B cells promoted IFNγ expression. Moreover, T cells activated in the presence of DCs were profoundly diabetogenic in an adoptive transfer system, unlike those co-stimulated with B cells. These data provide new insight into the regulation of CD4 T cell responses and how levels of IL-21 produced in vivo could modulate the balance between tolerance and immunity."]},{"key":"dc:format","label":"Dc Format","values":["application/pdf"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public","staffonly"]},{"key":"dc:title","label":"Title","values":["Role of Interleukin 21 in CD4 T cell regulation"]}]}],"canonical_facts":{"dc:contributor.sponsor":["na"],"dc:creator":["Attridge, Kesley Blair"],"dc:date":["2012-07"],"dc:date.issued":["2012-07"],"dc:description.abstract":["IL-21 is crucial for anti-viral defense, the germinal center reaction and anti-tumour immunity. Conversely, it has been implicated in various autoimmune conditions, including type-1 diabetes. This study set out to explore how IL-21 influences CD4 T cell immune responses, with particular emphasis on its ability to counteract Treg-mediated suppression. These experiments revealed that IL-21 acted on conventional CD4 T cells to release them from suppression. This was associated with loss of Treg homeostasis, as IL-21 was able to inhibit IL-2 production and could substitute for IL-2 in conventional but not regulatory T cells. Analysis of how CD4 T cell responses are controlled was broadened by investigation of the CTLA-4 pathway, a major regulator of T cell immunity. We showed that CTLA-4 could decrease the level of CD86 expression on APCs by trans-endocytosis in vivo, thereby limiting T cell CD28 signalling. In a further development, we showed that IL-21 could directly upregulate CD86 expression by B cells, illustrating the opposing functions of CTLA-4 and IL-21. Finally, we explored how the nature of T cell activation influences cytokine production and pathogenicity. These experiments revealed that IL-21 production by CD4 T cells was strongly induced during responses driven by DCs, whilst stimulation with B cells promoted IFNγ expression. Moreover, T cells activated in the presence of DCs were profoundly diabetogenic in an adoptive transfer system, unlike those co-stimulated with B cells. These data provide new insight into the regulation of CD4 T cell responses and how levels of IL-21 produced in vivo could modulate the balance between tolerance and immunity."],"dc:format":["application/pdf"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/3355/1/Attridge_12_PhD.pdf","http://etheses.bham.ac.uk//id/eprint/3355/2/Decl_IS_Attridge_12_PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","School of Immunity and Infection"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/3355/"],"dc:subject":["R Medicine (General)","RC Internal medicine"],"dcterms:accessrights":["public","staffonly"],"dc:title":["Role of Interleukin 21 in CD4 T cell regulation"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:27:08Z"}